Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, New Zealand.
Eur J Prev Cardiol. 2012 Jun;19(3):349-57. doi: 10.1177/1741826711403069. Epub 2011 Mar 14.
In New Zealand, a setting in which national guidelines recommend statins for all patients with coronary heart disease (CHD) and cost barriers are low, patterns of use of these drugs are unknown. We investigated dispensing rates after hospital discharge for acute CHD event.
Retrospective cohort study.
Drug dispensing, hospital diagnosis, and mortality records were linked by unique identifier for all New Zealanders aged 35-84 years after discharge following acute CHD event in 2007. We defined the statin dispensing ratio (SDR) as the proportion of days that 15,506 patients aged 35-84 years were dispensed such agents during the 12 months post discharge. An SDR ≥0.8 (80% or more days covered) was considered optimal.
Overall, 59% of the cohort had an SDR ≥0.8. Of patients dispensed statins in the 3 months before admission (n = 5506), almost all (99%; 5466) continued treatment during follow up and 82% had an SDR ≥0.8. In contrast, for patients not dispensed statins before admission (n = 8014), only two-thirds started statins during follow up and only 44% had an SDR ≥0.8. Of all patients with low statin dispensing (SDR <0.8), about one-quarter were not dispensed any lipid-lowering drugs, one-quarter received alternative lipid-lowering drugs, one-quarter stopped statins, and the remaining quarter were intermittent statin users.
In a setting with few barriers to statin treatment, about 40% of patients had suboptimal statin dispensing during the year after hospital treatment for CHD. This study has identified four significant categories of suboptimal adherence that could inform quality improvement programmes.
在新西兰,国家指南建议所有冠心病(CHD)患者使用他汀类药物,且成本障碍较低,因此尚不清楚这些药物的使用模式。我们调查了急性 CHD 事件出院后的配药率。
回顾性队列研究。
通过唯一标识符将所有年龄在 35-84 岁的新西兰人在 2007 年急性 CHD 事件出院后的药物配药、医院诊断和死亡率记录进行了链接。我们将他汀类药物配药率(SDR)定义为在出院后 12 个月内,15506 名年龄在 35-84 岁的患者中有多少天配给了这些药物。SDR≥0.8(覆盖 80%或更多天)被认为是最佳的。
总体而言,59%的队列患者的 SDR≥0.8。在入院前 3 个月配给了他汀类药物的患者(n=5506)中,几乎所有人(99%,5466)在随访期间继续治疗,82%的患者 SDR≥0.8。相比之下,在入院前未配给他汀类药物的患者(n=8014)中,只有三分之二的患者在随访期间开始使用他汀类药物,只有 44%的患者 SDR≥0.8。在所有低他汀类药物配药(SDR<0.8)的患者中,约四分之一的患者未配给任何降脂药物,四分之一的患者接受了替代降脂药物,四分之一的患者停止了使用他汀类药物,其余四分之一的患者为间歇性使用他汀类药物。
在他汀类药物治疗障碍较少的环境中,约 40%的患者在 CHD 住院治疗后的一年中他汀类药物的配药情况不理想。本研究确定了四个显著的不依从类别,这可以为质量改进计划提供信息。